Data from a large Phase 3 trial of a new hormone therapy, abiraterone, for men with prostate cancer has been called significant by a prostate cancer expert at Cancer Research UK. The data showed the drug gave a nearly four-month survival advantage. ---Subscribe to MedNous to access this article--- Company News
